[Federal Register Volume 59, Number 75 (Tuesday, April 19, 1994)]
[Unknown Section]
[Page 0]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 94-9351]


[[Page Unknown]]

[Federal Register: April 19, 1994]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES
[Docket No. 94M-0060]

 

Stellar Contact Lens, Inc.; Premarket Approval of OP-3TM 
(Lotifocon A) Rigid Gas Permeable Contact Lens (Clear and Tinted)

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) is announcing its 
approval of the application by Stellar Contract Lens, Inc., Chicago, 
IL, for premarket approval, under section 515 of the Federal Food, 
Drug, and Cosmetic Act (the act), of the OP-3TM (lotifocon A) 
Rigid Gas Permeable Contact Lens (Clear and Tinted). FDA's Center for 
Devices and Radiological Health (CDRH) notified the applicant, by 
letter of January 24, 1994, of the approval of the application.

DATES: Petitions for administrative review by May 19, 1994.

ADDRESSES: Written requests for copies of the summary of safety and 
effectiveness data and petitions for administrative review to the 
Dockets Management Branch (HFA-305), Food and Drug Administration, rm. 
1-23, 12420 Parklawn Dr., Rockville, MD 20857.

FOR FURTHER INFORMATION CONTACT: James F. Saviola, Center for Devices 
and Radiological Health (HFZ-460), Food and Drug Administration, 1390 
Piccard Dr., Rockville, MD 20850, 301-594-1744.

SUPPLEMENTARY INFORMATION: On September 8, 1992, Stellar Contact Lens, 
Inc., Chicago, IL 60611, submitted to CDRH an application for premarket 
approval of the OP-3TM (lotifocon A) Rigid Gas Permeable Contact 
Lens (Clear and Tinted). The device is indicated for daily wear for the 
correction of visual acuity in not-aphakic persons with nondiseased 
eyes that are myopic or hyperopic. The lens may be worn by persons who 
may exhibit astigmatism of 2.50 diopters or less that does not 
interfere with visual acuity. The tinted lens contains the color 
additive listing provisions of 21 CFR 74.3206.
    In accordance with the provisions of section 515(c)(2) of the act 
as amended by the Safe Medical Devices Act of 1990, this premarket 
approval application (PMA) was not referred to the Ophthalmic Devices 
Panel, an FDA advisory panel, for review and recommendation because the 
information in the PMA substantially duplicates information previously 
reviewed by this panel. On January 24, 1994, CDRH approved the 
application by a letter to the applicant from the Acting Director of 
the Office of Device Evaluation, CDRH.
    A summary of the safety and effectiveness data on which CDRH based 
its approval is on file in the Dockets Management Branch (address 
above) and is available from that office upon written request. Requests 
should be identified with the name of the device and the docket number 
found in brackets in the heading of this document.

Opportunity for Administrative Review

    Section 515(d)(3) of the act (21 U.S.C. 360e(d)(3)) authorizes any 
interested person to petition, under section 515(g) of the act (21 
U.S.C. 360e(g)), for administrative review of CDRH's decision to 
approve this application. A petitioner may request either a formal 
hearing under part 12 (21 CFR part 12) of FDA's administrative 
practices and procedures regulations or a review of the application and 
CDRH's action by an independent advisory committee of experts. A 
petition is to be in the form of a petition for reconsideration under 
Sec. 10.33(b) (21 CFR 10.33(b)). A petitioner shall identify the form 
of review requested (hearing or independent advisory committee) and 
shall submit with the petition supporting data and information showing 
that there is a genuine and substantial issue of material fact for 
resolution through administrative review. After reviewing the petition, 
FDA will decide whether to grant or deny the petition and will publish 
a notice of its decision in the Federal Register. If FDA grants the 
petition, the notice will state the issue to be reviewed, the form of 
review to be used, the persons who may participate in the review, the 
time and place where the review will occur, and other details.
    Petitioners may, at any time on or before May 19, 1994, file with 
the Dockets Management Branch (address above) two copies of each 
petition and supporting data and information, identified with the name 
of the device and the docket number found in brackets in the heading of 
this document. Received petitions may be seen in the office above 
between 9 a.m. and 4 p.m., Monday through Friday.
    This notice is issued under the Federal Food, Drug, and Cosmetic 
Act (secs. 515(d), 520(h) (21 U.S.C. 360e(d), 360j(h))) and under 
authority delegated to the Commissioner of Food and Drugs (21 CFR 5.10) 
and redelegated to the Center for Devices and Radiological Health (21 
CFR 5.53).

    Dated: April 5, 1994.
 Joseph A. Levitt,
 Deputy Director for Regulations Policy, Center for Devices and 
Radiological Health.
[FR Doc. 94-9351 Filed 4-18-94; 8:45 am]
BILLING CODE 4160-01-F